FCM
PRAX icon

Fieldview Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Fieldview Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,223
Closed -$394K – 667
2026
Q1 		$394K Buy
+1,223
New +$378K 0.12% 315

Other funds holding PRAX

JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Fieldview Capital Management's PRAX Position: Q2 2026 in Review

Fieldview Capital Management sold out of Praxis Precision Medicines (PRAX) in Q2 2026, closing a stake of 1,223 shares — an estimated $394K sold.

Fieldview Capital Management first reported a position in PRAX in Q1 2026 and held it in 1 quarter. The position peaked at $394K in Q1 2026. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

  • Fieldview Capital Management reported no remaining Praxis Precision Medicines position as of Q2 2026 after selling out during the quarter.
  • Fieldview Capital Management sold 1,223 Praxis Precision Medicines shares in Q2 2026, an estimated $394K.
  • Fieldview Capital Management first reported a position in Praxis Precision Medicines in Q1 2026 and held it in 1 quarter.
  • Fieldview Capital Management's Praxis Precision Medicines position peaked at $394K in Q1 2026.
  • 309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Fieldview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.